74 related articles for article (PubMed ID: 34609091)
1. Disparities between Uptake of Germline
Hur YM; Mun J; Kim MK; Lee M; Kim YH; Kim SC
J Korean Med Sci; 2021 Oct; 36(38):e241. PubMed ID: 34609091
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
[TBL] [Abstract][Full Text] [Related]
3. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Zaaijer LH; van Doorn HC; Mourits MJ; van Beurden M; de Hullu JA; Adank MA; van Lonkhuijzen LR; Vasen HF; Slangen BF; Gaarenstroom KN; Zweemer RP; Vencken PM; Seynaeve C; Kriege M
Br J Cancer; 2016 Nov; 115(10):1174-1178. PubMed ID: 27755534
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers.
Stuckey A; Dizon D; Scalia Wilbur J; Kent J; Tejada-Berges T; Gass J; Legare R
Gynecol Obstet Invest; 2010; 69(4):270-273. PubMed ID: 20090358
[TBL] [Abstract][Full Text] [Related]
5. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
6. BRCA testing in unaffected young women in the United States, 2006-2017.
Guo F; Scholl M; Fuchs EL; Berenson AB; Kuo YF
Cancer; 2020 Jan; 126(2):337-343. PubMed ID: 31568561
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan RD; Clamp AR; Barnes BM; Timms K; Schlecht H; Yarram-Smith L; Wallis Y; Valganon-Petrizan M; MacMahon S; White R; Morgan S; McKenna S; Hudson E; Tookman L; George A; Manchanda R; Sundar SS; Nicum S; Brenton JD; Kristeleit RS; Banerjee S; McNeish IA; Ledermann JA; Taylor SS; Evans DGR; Jayson GC
Int J Gynecol Cancer; 2023 Aug; 33(8):1253-1259. PubMed ID: 37072323
[TBL] [Abstract][Full Text] [Related]
8. A cost-utility analysis of
Lertwilaiwittaya P; Tantai N; Maneeon S; Kongbunrak S; Nonpanya N; Hurst ACE; Srinonprasert V; Pithukpakorn M
Front Public Health; 2023; 11():1257668. PubMed ID: 38162618
[TBL] [Abstract][Full Text] [Related]
9. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Quinn BA; Brake T; Hua X; Baxter-Jones K; Litwin S; Ellenson LH; Connolly DC
PLoS One; 2009 Dec; 4(12):e8404. PubMed ID: 20046879
[TBL] [Abstract][Full Text] [Related]
10. Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
Tortorella L; Cappuccio S; Giannarelli D; Nero C; Marchetti C; Gallotta V; Costantini B; Pasciuto T; Minucci A; Fagotti A; Scambia G
Gynecol Oncol; 2024 Mar; 182():57-62. PubMed ID: 38262239
[TBL] [Abstract][Full Text] [Related]
11. In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.
Hoskins LM; Werner-Lin A; Greene MH
PLoS One; 2014; 9(2):e87696. PubMed ID: 24586286
[TBL] [Abstract][Full Text] [Related]
12. Non-sclerosing (T-cell) and sclerosing (B-cell) lymphocytic lobulitis in diagnostic breast biopsies: Clinical, imaging, and pathologic features.
Ngo MH; Pinkus GS; Yeh ED; Brock JE; Schulte S; Lester SC
Hum Pathol; 2024 Apr; 146():28-34. PubMed ID: 38518977
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye.
Cicin I; Karadurmus N; Bilici A; Bahsi T; Sendur MA; Demirci U; Goksu SS; Er O; Bisgin A; Ozturk Saglam OF; Aver B; Kilickap S
Future Oncol; 2024 May; 20(15):1031-1045. PubMed ID: 38014519
[TBL] [Abstract][Full Text] [Related]
14. Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.
Cvelbar M; Hocevar M; Novakovic S; Stegel V; Perhavec A; Krajc M
Radiol Oncol; 2017 Jun; 51(2):187-194. PubMed ID: 28740454
[TBL] [Abstract][Full Text] [Related]
15. Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations.
Trivedi MS; Armstrong KA
JAMA Oncol; 2024 Apr; 10(4):435-436. PubMed ID: 38421667
[No Abstract] [Full Text] [Related]
16. Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?
Mauro LJ; Spartz A; Austin JR; Lange CA
Endocr Rev; 2023 Nov; 44(6):1029-1046. PubMed ID: 37261958
[TBL] [Abstract][Full Text] [Related]
17. Electronic medical record documentation of germline genetic evaluations in patients with ovarian cancer.
Batson M; Goldblatt LG; Pundock S; Arutyunov A; McKenna D; Haggerty A; Symecko H; Shah PD
J Genet Couns; 2024 Apr; 33(2):314-321. PubMed ID: 37183564
[TBL] [Abstract][Full Text] [Related]
18.
Lanjouw L; Bart J; Mourits MJE; Willems SM; van der Hout AH; Ter Elst A; de Bock GH
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730634
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cell Dysfunction in Premenopausal
Haran S; Chindera K; Sabry M; Wilkinson N; Arora R; Zubiak A; Bartlett TE; Evans I; Jones A; Reisel D; Herzog C; Alkasalias T; Newman M; Kim J; Rådestad AF; Gemzell-Danielsson K; Rosenthal AN; Dubeau L; Lowdell MW; Widschwendter M
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539519
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immortalized ovarian epithelial cells with BRCA1/2 mutation.
Komatsu H; Okawa M; Kazuki Y; Kazuki K; Hichiwa G; Shimoya K; Sato S; Taniguchi F; Oshimura M; Harada T
Hum Cell; 2024 Apr; ():. PubMed ID: 38615309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
